

Disclaimer

The information contained in this document is for general informational purposes only and does not constitute an offer, solicitation, invitation or recommendation to subscribe for or purchase any securities, or other products or to provide any investment advice or service of any kind. This document is solely intended for distribution to and use by professional investors. This document is not directed at, and is not intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hong Kong Exchanges and Clearing Limited ("HKEX") to any registration requirement within such jurisdiction or country.

This document contains forward-looking statements which are based on the current expectations, estimates, projections, beliefs and assumptions of HKEX about the businesses and the markets in which it and its subsidiaries operate. These forward-looking statements are not guarantees of future performance and are subject to market risk, uncertainties and factors beyond the control of HKEX. Therefore, actual outcomes and returns may differ materially from the assumptions made and the statements contained in this document.

Where this document refers to Shanghai-Hong Kong Stock Connect and/or Shenzhen-Hong Kong Stock Connect (together, the "Stock Connect" programs), please note that currently, access to northbound trading is only available to intermediaries licensed or regulated in Hong Kong; southbound trading is only available to intermediaries licensed or regulated in Mainland China. Direct access to the Stock Connect is not available outside Hong Kong and Mainland China.

Where this document refers to Bond Connect, please note that currently, access to northbound trading is only available to foreign investors that are able to trade onshore bonds on the China Foreign Exchange Trade System & National Interbank Funding Centre.

Although the information contained in this document is obtained or compiled from sources believed to be reliable, HKEX does not guarantee the accuracy, validity, timeliness or completeness of the information or data for any particular purpose, and shall not accept any responsibility for, or be liable for, errors, omissions or other inaccuracies in the information or for the consequences thereof. The information set out in this document is provided on an "as is" and "as available" basis and may be amended or changed. It is not a substitute for professional advice which takes account of your specific circumstances and nothing in this document constitutes legal advice. HKEX shall not be responsible or liable for any loss or damage, directly or indirectly, arising from the use of or reliance upon any information provided in this document.



Agenda

- 01 1H 2020 Key Highlights
- 02 | HKEX Group Financial Review
- 03 Business and Strategic Update
- 04 Appendix



1H 2020 Key Highlights

1 | Financial Performance

- Record half-yearly revenue and profit despite challenging macroeconomic backdrop with core business revenue up by 13%YoY; total revenue up by 2%YoY and PAT up by 1%YoY
- Record half-yearly Stock Connect revenue of HK\$743mn (+46%YoY)
- Net investment income fell HK\$681mn, primarily due to the fair value losses of collective investment schemes previously announced at Q1

2 | Business and Strategy

- Strong IPO Market #2 globally in number of new company listings (64) and #3 in IPO funds raised (HK\$92.8bn)
- Strong performance in Connect Schemes all achieved half-yearly record high ADT
- Major licensing agreement for MSCI Asia & EM indexes to offer suite of 37 new contracts, further expanding HKEX product ecosystem
- Ongoing market microstructure enhancements and technology capabilities enhancement

3 | In focus - A new Era of Liquidity in Hong Kong

- Premier, global fundraising venue for new economy and jumbo IPOs, contributing to increasing trading activities
- Holistic product ecosystem encompassing HK, international and onshore underlying





Key Financial Highlights

Record half-yearly revenue and profit Strong core business performance; market conditions impacted investment income

(HK\$)










- % is computed based on amounts reported in financial statements.
- 2. The 2020 first interim dividend will be payable in cash, without a scrip alternative.
- 3. Does not add up due to roundings.




1H 2020: Record Half-Yearly Revenue and Profit



- 1. Excludes depreciation and amortisation, finance costs, and share of profits/(losses) of joint ventures
- 2. For the purpose of this presentation, tax impact of NII is not considered when calculating the PAT attributable to NII.



Q2 2020: Quarterly Record High Due to Rebound of External Portfolio and Seasonality




^{1.} Excludes depreciation and amortisation, finance costs, and share of profits/(losses) of joint ventures



^{2.} The tax impact of NII is not considered when calculating the PAT attributable to NII.

1H 2020 Performance above Historical Trendline



1H 2020 performance reflects resiliency of core business despite macroeconomic and COVID-19 induced uncertainty.


- 1. Excludes depreciation and amortisation, finance costs, share of profits/(losses) of joint ventures, and non-recurring costs arising from the proposed combination with London Stock Exchange Group (LSEG)
- Dotted trend lines are illustrative and do not constitute a forward forecast.



Higher Revenue across All Business Segments, Offsetting External Portfolio Loss of HK\$138mn (versus a Record Gain of HK\$535mn in 1H 2019)

Segmental revenue

(HK\$ mn)




^{1.} Headline ADT up 20% (1H 2020: HK\$117.5bn; 1H 2019: HK\$97.9bn); ADT of cash equity up 33% (1H 2020: HK\$100.0bn; 1H 2019: HK\$75.1bn); ADT of DWs, CBBCs and warrants included under equity and financial derivatives down 23% (1H 2020: HK\$17.5bn; 1H 2019: HK\$22.8bn)




Investment Income – External Portfolio Impacted by Broader Market; Income from Internal Funds Held Up Well

- 1H 2020: HK\$838mn (1H 2019: HK\$1,519mn)
- Income from Internal Funds in line YoY despite increase in margin rebates to participants
- Average Margin Fund and Clearing House Fund sizes increased due to heightened volatility in 1H 2020 (in particular March)











External Portfolio – Annualised Return of 5.1% since Inception

Point of Injection / Redemption

Cumulative gain since inception (HK\$ mn)






As the market rebounded in Q2 2020, the external portfolio partially recovered from the Q1 2020 loss, resulting in a cumulative gain of \$1.2bn or an annualised return of 5.1% since inception.



^{1.} HKEX added HK\$2bn to the portfolio during the period from Q4 2018 to Q2 2019.

^{2.} HK\$3.3bn was redeemed in 1H 2020.


Resiliency and Performance reflected in EBITDA



The acquisition of BayConnect was completed in June 2019 and its opex is included under Technology segment.



Operating Expenses and Depreciation – Investment in Talent, Infrastructure and Strategic Initiatives



^{1.} Includes product marketing and promotion expenses





1 | Strong Market Performance

> Good Core Business Performance, against Challenging Macro Backdrop

- Strong performance in Cash Market and solid performance in derivatives and FICC
- Cash Market ADT +20%YoY at HK\$117.5bn
- Futures & Options ADV -0%YoY
- LME chargeable ADV +1%YoY

IPO Market, Strong Performance

- #2 globally in number of new company listings (64), including 15 New Economy and Biotech companies
- #3 in IPO funds raised (HK\$92.8bn), 29%YoY growth and 18% contributed by Biotech and Healthcare Sector
- Continued innovation and commitment to listed issuers, e.g. launched 20 new virtual listing ceremonies and first animated virtual listing in Asia with JD.com

> Strong Performance of Connect Schemes

- Stock Connect: Record half-yearly revenue of HK\$743mn (+46%YoY); Record volumes with Northbound ADT of RMB74.3bn (+69%YoY) and Southbound ADT of HK\$20.7bn (+86%YoY)
- Bond Connect: Record ADT of RMB19.9bn (+202%YoY)



2 | Strategic Plan on Track - 1H 2020 Highlights

Market Enhancement Programme Continues

- Northbound Master SPSA and Southbound Trading Investor Identification Regime launched
- Consultation conclusions published on Uncertificated Securities Market (USM); market consultation launched on Corporate WVR Beneficiaries
- Waiver on stamp duty for ETP market makers when creating and redeeming ETP units and new spread table since June for ETPs
- Shortened the listing cycle of structured products
- LME launched new rules to optimise warehousing network

New Products Launches

- Major agreement signed to licence a suite of MSCI indexes in Asia and Emerging Markets for the introduction of 37 futures and options contracts (33 already launched)
- USD and CNH Silver Futures; first Iron Ore Futures ETF; first active equity ETF; first commodity based L&I Product and 7 new stock option classes

> Technology Evolution

- Continue to leverage new technology (e.g. Al, blockchain, data) for modernisation and growth
- HKEX acquired a minority stake in Huakong TsingJiao Information Science (Beijing) Limited (TsingJiao)



3 | In Focus: New Era of Liquidity in Hong Kong

LISTINGS

Premier, global fundraising venue for <u>new economy and jumbo IPOs</u>

PRODUCTS

Holistic product ecosystem encompassing HK, international and onshore underlying

CLIENTS

<u>Convergence</u> of established <u>international and Mainland</u> market players



3 | In Focus: Strongly Performing IPO Market boosted by New Economy Issuers and Secondary Listings

2020 Jan - July Fundraising Summary

HK\$132.1bn

IPO Funds Raised (#3 globally)


+56%YoY

22 New Economy & Biotech Companies Listed... ...raising

HK\$94.8bn

+212%YoY

IPO Funds Raised by Segments




- World's second-largest fund raising hub for biotech companies
- Dialogue with the Biotech Community 2020 webinar series with PhiRDA - attracted 292,000+ views
- HKEX Biotech Week 2019 attended by 1,000+ scientists, biotech entrepreneurs, investors, technology experts and policymakers
- Ongoing listing reforms
 - Shortening of IPO settlement cycle
 - Enhancing listing regime for overseas issuers
 - Enhancing the bookbuilding and price discovery aspects of IPOs (cornerstone investors, pricing flexibility, clawback mechanism)

Source: Dealogic, as of July 2020.

- 1. Include Non-18A Biotech companies
- Only include Chapter 18A Biotech companies



3 | In Focus: HK - Asia's Largest and World's 2nd Largest Biotech Fundraising Hub



Hong Kong healthcare and biotech sector grew faster than both the US and the Mainland, and has huge potential to become even more sizable in coming years




3 | In Focus: Jumbo IPOs Contributing to Increased Trading Activity

14 Jumbo IPOs > US\$1bn (HK\$7.8bn) since Jan 2018

Rank	Company name	IPO date	IPO size (HK\$bn)	
1	Alibaba Group - SW	26/11/2019	101.20	
2	China Tower - H	08/08/2018	58.80	
3	Budweiser Brewing APAC	30/09/2019	45.08	
4	Xiaomi Corporation - W	09/07/2018	42.61	
5	Meituan Dianping - W	20/09/2018	33.14	
6	JD.COM - SW	18/06/2020	34.56	
7	Netease - S	11/06/2020	24.26	
8	ESR Cayman Ltd.	01/11/2019	14.06	
9	Shenwan Hongyuan - H	26/04/2019	9.09	
10	Hansoh Pharmaceutical Group	14/06/2019	9.04	
11	Topsports International Holdings	10/10/2019	9.01	
12	Ping An Healthcare and Technology	04/05/2018	8.77	
13	Jiangxi Bank - H	26/06/2018	8.60	
14	WuXi AppTec - H	13/12/2018	8.28	


Rising contribution to volumes from Jumbo IPOs



In 2020, 16% of cash ADT and 13% of stock option ADV is contributed by the top 14 IPOs over the last 2.5 years



3 | In Focus: Holistic Product Ecosystem



- ✓ BETTER PRICE DISCOVERY
- ✓ RISK MANAGEMENT / HEDGING
- ✓ ARBITRAGE OPPORTUNITIES
- ✓ CAPITAL EFFICIENCY


The launch of A-share¹, Asia and EM derivatives will further integrate our ecosystem of HK, international and onshore underlying



^{1.} HKEX signed a licence agreement with MSCI to introduce futures contracts on the MSCI China A Index, subject to regulatory approval and market conditions.

^{2.} HKEX signed a licence agreement with MSCI to introduce 37 futures and options contracts in Hong Kong based on a suite of indexes in Asia and Emerging Markets, subject to regulatory approval and market conditions.


3 | In Focus: The ETP Growth Story







3 | In Focus: Convergence of Established International and Mainland Market Players



- ✓ BROADER LIQUIDITY POOL
- **✓ DIVERSE SKILLSET**
- ✓ ABILITY TO BRIDGE DIFFERENCES
 IN MARKET STRUCTURES

Diverse mix of clients and market players have continued to establish their presence in Hong Kong



Looking Ahead

- Macro geopolitical and economic outlook remains uncertain: resiliency, adaptability and sustainability will continue to be key
- ➤ A prolonged COVID-19 outbreak, escalating China-US tensions, and the imminent US election will be drivers of sentiment and shape headlines
- We expect Hong Kong to continue to play a significant role as an IFC
- We anticipate economic fragility and a low interest rate environment to persist, which may impact HKEX investment income
- > HKEX core businesses, across markets and asset class, remain well-placed and robust
- Recent 'Jumbo' listings; confirmation of a strong IPO pipeline; range of new product launches; market structure enhancements; and the recently announced MSCI/HKEX futures contracts deal have all helped boost liquidity and market sentiment
- ➤ Continuing to build our markets' diversity and attractiveness, strong cost discipline, active risk management and further executing against our Strategic Plan will be cornerstones of the second half of 2020







Financial Highlights – Income Statement

(HK\$ mn, unless stated otherwise)	1H 2020	% of Revenue & Other Income	1H 2019	% of Revenue & Other Income	YoY Change
Results					
Revenue and other income	8,782	100%	8,578	100%	2%
Operating expenses	(2,076)	(24%)	(1,953)	(23%)	6%
EBITDA	6,706	76%	6,625	77%	1%
Depreciation and amortisation	(545)	(6%)	(495)	(6%)	10%
Operating profit	6,161	70%	6,130	71%	1%
Finance costs and share of profits less losses of joint ventures	(57)	(1%)	(80)	(1%)	(29%)
Profit before taxation	6,104	70%	6,050	71%	1%
Taxation	(870)	(10%)	(847)	(10%)	3%
(Profit)/loss attributable to non-controlling interests	(1)	(0%)	2	0%	N/A
Profit attributable to HKEX shareholders	5,233	60%	5,205	61%	1%
Capex	519		368		41%
Basic earnings per share	HK\$4.15		HK\$4.16		(0%)
Headline ADT on the Stock Exchange	HK\$117.5 bn		HK\$97.9 bn		20%

^{1. %} does not add up due to roundings.



Performance by Operating Segment


HK\$ mn	Cash Equity	Equity & Financial Derivatives	Commodities	Post Trade	Technology	Corporate Items	Group 1H 2020	Group 1H 2019
Revenue and other income	2,253	1,638	749	3,629	443	70	8,782	8,578
% of Group Total	26%	19%	8%	41%	5%	1%	100%	100%
Operating expenses	(285)	(307)	(329)	(432)	(139)	(584)	(2,076)	(1,953)
EBITDA	1,968	1,331	420	3,197	304	(514)	6,706	6,625
% of Group Total (1)	29%	20%	6%	48%	5%	(8%)	100%	100%
EBITDA margin	87%	81%	56%	88%	69%	N/A	76 %	77%
Depreciation and amortisation	(60)	(51)	(169)	(106)	(22)	(137)	(545)	(495)
Finance costs	(7)	(6)	(4)	(46)	(1)	(32)	(96)	(86)
Share of profits less losses of joint ventures	39	-	-	-	-	-	39	6
Profit before taxation	1,940	1,274	247	3,045	281	(683)	6,104	6,050

^{1. %} Share of Group EBITDA (including Corporate Items).



Stock Connect – Trading Trends

Stock Connect generated record revenue of HK\$743mn in 1H 2020, 46% higher than 1H 2019 (Full Year 2019: HK\$1,009mn)



Stock Connect Northbound and Southbound Trading ADT reached RMB74.3bn and HK\$20.7bn in 1H 2020

Stock Connect revenue continued to set record highs, reaching 8 per cent of the Group's total revenue and other income in 1H 2020 (1H 2019: 6 per cent)



Source: HKEX, SSE and SZSE as of Jul 2020

- 1. Northbound (NB) trading is conducted in RMB; The NB figures in the chart are converted to HKD based on the month-end exchange rate.
- 2. Does not add up due to roundings

